Weekly Recap | VG Health -3.39%, falling below its 20-day average
I'm LongbridgeAI, I can summarize articles.VG Health (VHT.US) fell from $321.66 to $310.74 this week, a decline of 3.39%, while the S&P 500 was down 0.8%. The ETF underperformed the benchmark by about 2.59 percentage points. It was a four-day trading week, starting Tuesday at $316.63 and closing that day at $314.61. Prices then drifted lower on Wednesday and Thursday, with Friday’s low touching $310.30 before the week ended at $310.74. The weekly range was 2.12%, with the close sitting below the 20-day moving average of $320.
The Week
VG Health (VHT.US) fell from $321.66 to $310.74 this week, a decline of 3.39%, while the S&P 500 was down 0.8%. The ETF underperformed the benchmark by about 2.59 percentage points. It was a four-day trading week, starting Tuesday at $316.63 and closing that day at $314.61. Prices then drifted lower on Wednesday and Thursday, with Friday’s low touching $310.30 before the week ended at $310.74. The weekly range was 2.12%, with the close sitting below the 20-day moving average of $320.89 but still above the 60-day average of $309.04.
Sector News
Healthcare was active this week, though the tone was mixed. Novartis’s late-stage cholesterol drug trial failed, triggering a broad biopharma selloff mid-week and dragging Amgen toward its worst single day since October 2000. At the same time, Abbott won FDA approval for its TactiFlex Duo ablation catheter, and AstraZeneca secured a new breast cancer treatment approval while also reporting extended survival for a lung cancer combination in a late-stage study. AbbVie highlighted growth in SKYRIZI and RINVOQ at the Wells Fargo conference and said its menstrual migraine therapy met the primary goal of a late-stage study. Johnson & Johnson received CE marking for ACUVUE OASYS MAX contact lenses, and Bloomberg reported Apollo Global is in talks to acquire J&J’s orthopedics unit. The stock-specific news was split, leaving the ETF to absorb broader sector-level pressure.
The Week Ahead
On Tuesday next week, the New York Fed manufacturing index is due, with the prior reading at 20.6 and the consensus forecast at 14.75. Wednesday brings a batch of US data: retail sales, retail sales ex-autos, import prices, the NAHB housing market index, and the EIA’s weekly crude and Cushing inventory reports. These macro releases offer clues on demand conditions and could influence risk appetite across the healthcare sector.
In Short
VHT.US moved lower in line with the broader market but with a deeper drawdown, suggesting the healthcare space carried extra weight this week. Sector news was split, with the Novartis trial failure dominating risk sentiment, while positive updates from Abbott, AstraZeneca, AbbVie, and Johnson & Johnson failed to shift the ETF’s overall direction. In the latest trading day, small-lot flows showed net buying, but medium and large lots were absent from the tape. The focus next turns to whether macro data can ease sector pressure and whether the ETF can reclaim its 20-day moving average.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.